Skip to main content

Advertisement

Log in

Use of triclabendazole for treatment of patients co-infected by Fasciola spp. and S. mansoni in Behera Governorate, Egypt

  • Original Paper
  • Published:
Parasitology Research Aims and scope Submit manuscript

Abstract

Praziquantel is still very effective for the treatment of schistosomiasis, but there are rising concerns on the potential risk of developing resistances because of the extensive use of this drug. Triclabendazole, a systemic anthelmintic, is very effective against other trematodes such as Paragonimus spp. and Fasciola spp. It has been reported to be effective in vitro and in experimental animals against Schistosoma mansoni. However, its antischistosomal efficacy in humans has not yet been evaluated. The objective of the study was to evaluate the efficacy of triclabendazole at the dosage currently used for the treatment of human fascioliasis (10mg/kg body weight) in subjects co-infected with S. mansoni and Fasciola spp. The study was carried out in Behera, a highly endemic area for both parasites, by personnel of the Egyptian Ministry of Health and Population. Ten subjects (m = 4, f = 6; age, 8–58years), who were infected at the same time by Fasciola spp. and S. mansoni, were enrolled. Six weeks after therapy, seven subjects were still excreting ova of S. mansoni, whereas none was excreting Fasciola spp. ova. At the given dosage, triclabendazole appeared not to be sufficiently effective in the treatment of S. mansoni.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Bundy DAP, Hall A, Medley GF, Savioli L (1992) Evaluating measures to control intestinal parasitic infections. World Health Stat Q 45:168–179

    PubMed  CAS  Google Scholar 

  • Calvopina M, Guderian RH, Paredes W, Cooper PJ (2003) Comparison of two single-day regimens of triclabendazole for the treatment of human pulmonary paragonimiasis. Trans R Soc Trop Med Hyg 97:451–454

    Article  PubMed  CAS  Google Scholar 

  • Curtale F, Hassanein YAW, El Wakeel A, Barduagni P, Savioli L (2003) The school health programme in Behera: an integrated helminth control programme at governorate level in Egypt. Acta Trop 86:295–307

    Article  PubMed  Google Scholar 

  • El Sayed MH, Allam AF, (1997) effect of triclabendazole on the tegument of Schistosoma mansoni: a scanning electron microscopic study.. J Egypt Soc Parasitol 7::43–152

    Google Scholar 

  • Keiser J, El Ela NA, El Lakkany N, Diab T, Chollet J, Utzinger J, Barakat R (2006) Triclabendazole and its two main metabolites lack activity against Schistosoma mansoni in mouse model. Am J Trop Med Hyg 75:287–291

    PubMed  CAS  Google Scholar 

  • Khalil SS (2000) On the schistosomicidial effect of triclabendazole: an experimental study. J Egypt Soc Parasitol 30:799–808

    PubMed  CAS  Google Scholar 

  • Mansoury ST (1997) Effect of two trematodicidal drugs on the morphology and tegumentary ultrastructure of Schistosoma mansoni. J Egypt Soc Parasitol 27:233–241

    PubMed  CAS  Google Scholar 

  • Millán JC, Mull R, Freise S, Richter J, For the Triclabendazole Study Group (2000) The efficacy and tolerability of triclabendazole in Cuban patients with latent and chronic Fasciola hepatica infection. Am J Trop Med Hyg 63:264–269

    PubMed  Google Scholar 

  • Polman K, Stelma FF, Le Cessie S, De Vias SJ, Falcao Ferreira ST, Tallia I, Deelder AM, Gryseels B (2002) Evaluation of the patterns of Schistosoma mansoni infection and re-infection in Senegal, from faecal egg counts and serum concentrations of circulating anodic antigen. Ann Trop Med Parasitol 96:679–689

    Article  PubMed  CAS  Google Scholar 

  • WHO (1994) Bench aids for the diagnosis of intestinal parasites. World Health Organization, Geneva

    Google Scholar 

  • WHO (1995) WHO model prescribing information. Drugs used in parasitic diseases., 2nd edn. World Health Organization, Geneva

    Google Scholar 

  • WHO (1998) Triclabendazole and fascioliasis—a new drug to combat an age-old disease. World Health Organization, Geneva (Fact sheet no. 191)

    Google Scholar 

Download references

Acknowledgment

The present study was implemented in the framework of the Egyptian–Italian Cooperation Programme “Support to the Health Sector Reform” between the PHC Department of the MoHP, Egypt, and the DGCS–Ministry of Foreign Affairs, Italy. Special thanks to Prof. Joachim Richter, University of Düsseldorf, Germany, for his constant encouragement and support to the study.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Filippo Curtale.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Barduagni, P., Hassanein, Y., Mohamed, M. et al. Use of triclabendazole for treatment of patients co-infected by Fasciola spp. and S. mansoni in Behera Governorate, Egypt. Parasitol Res 102, 631–633 (2008). https://doi.org/10.1007/s00436-007-0802-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00436-007-0802-6

Keywords

Navigation